Government ❯ Regulation ❯ FDA ❯ Drug Approval Process

Biologics License Application

FDA Setback Puts uniQure’s Huntington’s Gene Therapy Filing in Doubt

The agency signaled that Phase I/II results versus external controls would not provide the primary evidence for a BLA.

FDA Accepts Replimune’s Resubmitted RP1 Melanoma Filing, Sets April 2026 Decision